Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Huang, Haidong; Tsiouda, Theodora; Sardeli, Chrysanthi; Trakada, Georgia; Veletza, Lemonia; Kallianos, Anastasios; Kosmidis, Christoforos; Rapti, Aggeliki; Papaemmanouil, Liana; Hatzibougias, Dimitris; Drougas, Dimitrios; Bai, Chong; Hohenforst-Schmidt, Wolfgang

doi:10.1016/j.rmcr.2017.10.006

Cited by 19 publications

(11 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International Publisher electromagnetic navigation and cone beam ct bronchoscopy [1][2][3]. At advance stage disease we need tissue biopsies for non-small lung cancer patients in order to investigate the expression of a number of genes which are associated with the treatment options of a patient [4][5][6]. In specific we have to investigate the expression of epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene B-Raf (BRAF), proto-oncogene tyrosine-protein kinase-1 (ROS1) and programmed death-ligand-1 (PD-L1).…”

Section: Ivyspringmentioning

confidence: 99%

“…The tyrosine kinase inhibitors have pneumonitis, esophagitis and skin rash which is associated in most cases with the dosage [14,15]. Immunotherapy has orogonitis, pneumonitis, athritis, vitiligo, resurgence of hepatitis and disregulation of the thyroid gland [6,16] An aspect that has not been fully investigated is the differences of adverse effects, gender and disease response between chemotherapy and immunotherapy [17][18][19][20][21]. In the current research paper we investigated the differences of adverse effects between chemotherapy and immunotherapy in first line treatment for squamous cell carcinoma.…”

Section: Ivyspringmentioning

confidence: 99%

See 1 more Smart Citation

Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. Materials & Methods: Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. Results: 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. Conclusions: The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death.

show abstract

Section: Ivyspringmentioning

confidence: 99%

Section: Ivyspringmentioning

confidence: 99%

Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The mean onset delay is 31 weeks, similar to what observed in melanoma patients (Figure 3). In 2017, Zarogoulidis et al reported a case of leukoderma during anti-PD-1 therapy of lung adenocarcinoma [124], and a second case was reported one year later [125] (Figure 3). Leukoderma lesions were also reported in two patients affected by renal cell carcinoma and in patients with cholangiocarcinoma or squamous cell carcinoma [126,127].…”

Section: Melanoma-associated Leukoderma Beyond Melanomamentioning

confidence: 99%

Melanoma and Vitiligo: In Good Company

Failla

Carbone

Fortes

et al. 2019

IJMS

View full text Add to dashboard Cite

Cutaneous melanoma represents the most aggressive form of skin cancer, whereas vitiligo is an autoimmune disorder that leads to progressive destruction of skin melanocytes. However, vitiligo has been associated with cutaneous melanoma since the 1970s. Most of the antigens recognized by the immune system are expressed by both melanoma cells and normal melanocytes, explaining why the autoimmune response against melanocytes that led to vitiligo could be also present in melanoma patients. Leukoderma has been also observed as a side effect of melanoma immunotherapy and has always been associated with a favorable prognosis. In this review, we discuss several characteristics of the immune system responses shared by melanoma and vitiligo patients, as well as the significance of occurrence of leukoderma during immunotherapy, with special attention to check-point inhibitors.

show abstract

“…In any case it is a very efficient treatment modality. However; immunotherapy in lung cancer has numerous side effects such as tumor necrosis syndrome, vitiligo, psoriasis, acute thyroiditis and hepatitis resuscitation [ [20] , [21] , [22] , [23] ]. Uveitis, pancreatitis, central nervous system disease, and peripheral neuropathies have also been reported [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer

Sardeli

Romanidis

Οικονόμου

et al. 2020

Respiratory Medicine Case Reports

Self Cite

View full text Add to dashboard Cite

Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.

show abstract

Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Cited by 19 publications

References 23 publications

Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

Melanoma and Vitiligo: In Good Company

Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer

Contact Info

Product

Resources

About